MarketCapExport financials
Rigel Pharmaceuticals (RIGL)
The export includes the complete available history of financial statements and ratios. Numbers are provided in full, without million or billion abbreviations, in their original reporting units.
CSV downloads as a ZIP archive with one file for each report and frequency.
Facebook
X
Telegram
Rigel Pharmaceuticals Income Statement 2025-2008 | RIGL
Brief overview of income trends at Rigel Pharmaceuticals
The figures are compared over a five-year interval. Revenue reported by Rigel Pharmaceuticals was $109 million at the beginning of the period and $294 million at the end. Across the full period, sales moved by +170.9%; the average annual rate was 22.1%. The annual growth rate indicates an exceptionally strong top-line trend.
The five-year change in gross profit reached +155%: from 108 million dollars to 275 million dollars. The cost base moved against the top-line trend and weighed on the gross result. Comparing the endpoints gives gross margins of 99.2% and 93.3%. Weakening gross profitability reduces the quality of the top-line trend.
EBITDA changed from −28.3 million dollars to 128 million dollars (+552.4%). Operating profitability strengthened faster than the scale of sales. EBITDA margin moved from −26% to 43.5%. The company improved its ability to convert sales into EBITDA.
Net income moved from −29.7 million dollars at the start to 367 million dollars at the end. The company restored profitability by the end of the period.
Market value was $614 million at the start and $598 million at the end. The valuation did not keep pace with the reported progress.
Summary assessment
The financial profile remains mixed, with strengths and risks moving in different directions. The strongest signals are higher operating efficiency, net-income growth and sales growth. The overall view is constrained by a lower gross margin. The next reporting periods will show whether revenue, margins, and final profitability can strengthen.
Annual Income Statement Rigel Pharmaceuticals
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Market Cap |
598 M | 393 M | 25.9 M | 25.2 M | 436 M | 614 M | 392 M | 348 M | 504 M | 196 M | 243 M | 181 M | 275 M | 479 M | 615 M | 3.5 B | 3.53 B | - |
Shares |
18 M | 17.6 M | 17.4 M | 17 M | 170 M | 169 M | 167 M | 161 M | 126 M | 94.4 M | 88.4 M | 87.7 M | 87.3 M | 75 M | 63.3 M | 52.1 M | 40.9 M | - |
Historical Prices |
33.2 | 22.4 | 1.49 | 1.48 | 2.56 | 3.64 | 2.26 | 2.16 | 4 | 2.08 | 2.75 | 2.07 | 3.03 | 6.56 | 9.77 | 67.3 | 86.3 | 235 |
Net Income |
367 M | 17.5 M | -25.1 M | -58.6 M | -17.9 M | -29.7 M | -66.9 M | -70.5 M | -78 M | -69.2 M | -51.5 M | -90.9 M | -89 M | -98.8 M | -86 M | 37.9 M | -112 M | - |
Revenue |
294 M | 179 M | 117 M | 120 M | 149 M | 109 M | 59.3 M | 44.5 M | 4.48 M | 20.4 M | 28.9 M | 8.25 M | 7.15 M | 2.25 M | 4.75 M | - | - | - |
Cost of Revenue |
19.6 M | 18.6 M | 7.11 M | 1.75 M | 1.08 M | 895 K | 906 K | 287 K | - | - | - | - | - | - | - | - | - | - |
Gross Profit |
275 M | 161 M | 110 M | 118 M | 148 M | 17.4 M | 58.4 M | 44.2 M | - | - | 28.9 M | 8.25 M | 7.15 M | 2.25 M | 4.75 M | - | - | - |
Operating Income |
125 M | 24.2 M | -20.5 M | -55.6 M | -12.5 M | -29 M | -69.1 M | -72.7 M | -79.6 M | -69.7 M | -51.7 M | -91.2 M | -89.5 M | -99.4 M | -86.4 M | 35.3 M | -112 M | - |
Interest Expense |
- | 7.92 M | 6.87 M | 3.71 M | 4.86 M | 1.35 M | 335 K | - | - | - | - | - | - | - | 25 K | 91 K | 203 K | - |
EBITDA |
128 M | 26.4 M | -19.3 M | -54.6 M | -11.3 M | -28.3 M | -68.4 M | -72.1 M | -79.2 M | -63 M | -50.3 M | -88.9 M | -85.2 M | -96.9 M | -84.4 M | 36.6 M | -111 M | - |
Operating Expenses |
149 M | 136 M | 130 M | 174 M | 161 M | 46.4 M | 127 M | 117 M | 84.1 M | 84.4 M | 80.6 M | 99.5 M | 94.9 M | 102 M | 91.1 M | - | - | - |
General and Administrative Expenses |
116 M | 113 M | 106 M | 112 M | 91.9 M | 76.6 M | 74.6 M | 70 M | 37.8 M | 20.9 M | 17.8 M | 31.8 M | 19.6 M | 22.8 M | 21.8 M | 25.3 M | 20.9 M | - |
Annual performance
Select metrics to display
All numbers in USD currency
Quarterly Income Statement Rigel Pharmaceuticals
| 2026-Q3 | 2026-Q2 | 2026-Q1 | 2025-Q4 | 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Shares |
18.7 M | 18.5 M | 18.4 M | 75 M | 18 M | 17.9 M | 17.8 M | 23 K | 17.6 M | 17.5 M | 17.5 M | 12 K | 17.4 M | 17.4 M | 174 M | -155 M | 173 M | 172 M | 172 M | -340 M | 171 M | 170 M | 170 M | 169 M | 169 M | 169 M | 168 M | 168 M | 168 M | 167 M | 167 M | 167 M | 166 M | 162 M | 147 M | 144 M | 125 M | 122 M | 114 M | 99 M | 95.5 M | 92.5 M | 90.6 M | 89 M | 88.5 M | 88.1 M | 88 M | 87.8 M | 87.8 M | 87.5 M | 87.5 M | 87.4 M | 87.4 M | 87.1 M | 87.1 M | 85.3 M | 71.6 M | 71.5 M | 71.4 M | 71.2 M | 71.2 M | 58.3 M | 52.3 M |
Net Income |
13.2 M | 17.3 M | 8.65 M | 268 M | 27.9 M | 59.6 M | 11.4 M | 14.3 M | 12.4 M | -1.03 M | -8.25 M | 737 K | -5.69 M | -6.6 M | -13.5 M | 1.4 M | -19 M | -13.5 M | -27.4 M | -22.6 M | -21 M | -13.8 M | 39.5 M | -19.2 M | -14.2 M | -17.6 M | 21.2 M | -17.2 M | -11.5 M | -20.6 M | -17.6 M | 3.23 M | -23.8 M | -25.6 M | -24.4 M | -25.9 M | -52.1 M | -34.5 M | -15.3 M | -15.6 M | -53.6 M | -31 M | -17.5 M | -12.7 M | -6.67 M | -13.9 M | -18.2 M | -22.3 M | -20.9 M | -25.4 M | -22.3 M | -16.9 M | -23.8 M | -22.8 M | -25.6 M | -25.5 M | -25.5 M | -24.7 M | -23.2 M | -25.8 M | -17.9 M | -21.5 M | -20.8 M |
Revenue |
80.9 M | 78.7 M | 58.8 M | 69.8 M | 69.5 M | 102 M | 53.3 M | 57.6 M | 55.3 M | 36.8 M | 29.5 M | 35.8 M | 28.1 M | 26.9 M | 26.1 M | 51.3 M | 22.4 M | 29.8 M | 16.7 M | 20.4 M | 21.5 M | 26.3 M | 81 M | 18.4 M | 18.4 M | 16 M | 55.8 M | 15.4 M | 20.9 M | 10.4 M | 12.6 M | 37.9 M | 4.86 M | 1.79 M | - | - | 900 K | 3.58 M | 3.58 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Cost of Revenue |
10.8 M | 8.52 M | 4.61 M | 5.96 M | 4.75 M | 4.5 M | 4.41 M | 5.79 M | 8.03 M | 2.81 M | 2.02 M | 3.79 M | 1.27 M | 1.08 M | 977 K | 342 K | 250 K | 1.04 M | 121 K | 487 K | 151 K | 129 K | 316 K | 321 K | 140 K | 279 K | 155 K | 178 K | 310 K | 311 K | 107 K | 188 K | 69 K | 30 K | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Gross Profit |
70.1 M | 70.2 M | 54.2 M | 63.8 M | 64.7 M | 97.2 M | 48.9 M | 51.8 M | 47.3 M | 34 M | 27.5 M | 32 M | 26.9 M | 25.8 M | 25.1 M | 50.9 M | 22.2 M | 28.8 M | 16.6 M | 19.9 M | 21.4 M | 26.1 M | 80.7 M | 17.4 M | 16.1 M | 14.7 M | 12.5 M | 13.7 M | 11.4 M | 9.86 M | 7.95 M | 7.11 M | 4.8 M | 1.76 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Operating Income |
17.1 M | 23.6 M | 11.9 M | 23.2 M | 28.4 M | 61.1 M | 12.8 M | 16.7 M | 14.1 M | 447 K | -6.97 M | 1.97 M | -4.46 M | -5.27 M | -12.7 M | 2.08 M | -18.4 M | -13 M | -26.3 M | -21.4 M | -19.8 M | -13 M | 41.8 M | -18.8 M | -13.8 M | -17.4 M | 21 M | -17.3 M | -12 M | -21.3 M | -18.4 M | 2.53 M | -24.4 M | -26.1 M | -24.7 M | - | -17.9 M | -19.3 M | -16.2 M | - | -22.7 M | -13.6 M | -17.6 M | - | -6.78 M | -14 M | -18.2 M | - | -21 M | -25.5 M | -22.4 M | - | -23.9 M | -22.9 M | -25.7 M | - | -25.6 M | -24.9 M | -23.3 M | - | -18 M | -21.6 M | -20.9 M |
Interest Expense |
- | - | - | - | 1.89 M | 1.87 M | 1.85 M | 1.96 M | 2.06 M | 2.03 M | 1.87 M | 1.91 M | 1.9 M | 1.86 M | 1.2 M | 1.11 M | 826 K | 569 K | 1.2 M | 1.3 M | 1.32 M | 1.76 M | 485 K | 429 K | 429 K | 353 K | 142 K | 327 K | 8 K | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 4 K | 7 K | 11 K |
EBITDA |
17.1 M | 24.4 M | 12.5 M | 23.8 M | 29 M | 61.7 M | 13.4 M | 17.2 M | 14.7 M | 1.05 M | -6.57 M | 2.27 M | -4.16 M | -4.97 M | -12.4 M | 1.46 M | -18.2 M | -12.7 M | -26 M | -21 M | -19.5 M | -12.8 M | 42 M | -18.6 M | -13.6 M | -17.2 M | 21.2 M | -17.2 M | -11.9 M | -21.2 M | -18.2 M | 2.7 M | -24.2 M | -25.8 M | -24.6 M | - | -17.5 M | -19.1 M | -16.1 M | - | -21.9 M | -13.1 M | -17.2 M | - | -5.68 M | -13.2 M | -17.8 M | - | -19.2 M | -24.2 M | -21.7 M | - | -22 M | -21.6 M | -25 M | - | -23.8 M | -23.7 M | -22.8 M | - | -16.6 M | -20.6 M | -20.4 M |
Operating Expenses |
53 M | 46.6 M | 42.3 M | 40.7 M | 36.3 M | 36.1 M | 36.2 M | 35.2 M | 33.2 M | 33.6 M | 34.5 M | 30 M | 31.3 M | 31.1 M | 37.8 M | 48.9 M | 40.6 M | 41.7 M | 42.9 M | 41.3 M | 41.2 M | 39.2 M | 38.9 M | 36.3 M | 29.9 M | 32.1 M | -8.5 M | 31 M | 23.4 M | 31.2 M | 26.3 M | 4.58 M | 29.2 M | 27.9 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
General and Administrative Expenses |
34.7 M | 32.6 M | 30.7 M | 30 M | 28.9 M | 29.3 M | 27.7 M | 29.5 M | 27 M | 28 M | 28.4 M | 26.8 M | 24.9 M | 26.3 M | 27.7 M | 32.2 M | 25.9 M | 27 M | 27.4 M | 24.5 M | 22.9 M | 22.4 M | 22.1 M | 21.8 M | 17.4 M | 18.9 M | 18.4 M | 18.3 M | 18.1 M | 18.2 M | 19.9 M | 21.4 M | 18.1 M | 17.1 M | 13.5 M | - | 7.95 M | 7.82 M | 7.41 M | - | 4.56 M | 4.77 M | 4.42 M | - | 4.28 M | 4.1 M | 4.72 M | - | 4.89 M | 5.39 M | 5.52 M | - | 4.68 M | 4.89 M | 5.4 M | - | 5.38 M | 5.46 M | 6.16 M | - | 5.08 M | 4.84 M | 5.75 M |
Quarterly performance
Select metrics to display
All numbers in USD currency
The income statement is one of the three key financial reports of a company Rigel Pharmaceuticals (alongside the balance sheet and the cash flow statement). It shows how the company makes money and what its expenses are:
- How much revenue the company earned
- How much it spent on production, personnel, marketing, taxes, etc.
- What profit remained in the end
Analyzing the income statement helps an investor understand whether the business generates stable and growing profits, how effectively the company controls its expenses, and whether it is capable of generating income in the future. Additionally, this analysis shows how the company copes with crises and economic cycles, and allows assessing the potential for stock price growth and dividend payments.
Features- The income statement may include both recurring and one-time items (for example, profit from the sale of assets). It is necessary to separate core metrics from one-off events for accurate analysis.
- Companies often publish interim reports (e.g., quarterly), which allows for more timely tracking of trends.
- A combined analysis of the income statement with the balance sheet and cash flow statement provides a comprehensive view of the company’s financial health.
Russia
USA
Canada
Niderland
Israel
Schweiz
Australia
Britain
